Cases
Loxo Oncology, Inc. (LOXO)
Merger
Overview
Overview
- Date:
- 1/7/2019
- Company Name:
- Loxo Oncology, Inc.
- Stock Symbol:
- LOXO
- Company Name - Buyer:
- Eli Lilly and Company
- Stock Symbol - Buyer:
- LLY
- Status:
- Closed/Complete
- Merger Announcement Date:
- 1/7/2019
NEW YORK, January 7, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Loxo Oncology, Inc. (NASDAQ: LOXO) on behalf of stockholders concerning the proposed acquisition of the company by Eli Lilly and Company (NYSE: LLY).
Pursuant to the proposed transaction, announced on January 7, 2019 and valued at $8 billion, Loxo stockholders will receive $235.00 in cash for each share of Loxo common stock owned. The investigation focuses on whether Loxo and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Loxo Oncology shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.
Pursuant to the proposed transaction, announced on January 7, 2019 and valued at $8 billion, Loxo stockholders will receive $235.00 in cash for each share of Loxo common stock owned. The investigation focuses on whether Loxo and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Loxo Oncology shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.